ArticleInternational journal of biological sciences2026
GLUT3 drives paclitaxel resistance in peritoneal metastatic gastric cancer by promoting H3K18 lactylation-mediated MAPKAP1 transcription to suppress ferroptosis.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Paclitaxel-based intraperitoneal chemotherapy (IPC) is a cornerstone strategy for treating gastric cancer peritoneal metastasis (GCPM). However, a subset of patients exhibit resistance to this therapy. Our study revealed that glucose transporter type 3 (GLUT3) is a key mediator of paclitaxel resistance in GCPM, although its precise mechanism of action remains to be fully elucidated. Methods: Single-cell (nucleus) sequencing and immunohistochemical staining were used to analyze paclitaxel-resistant and paclitaxel-sensitive GCPM tissue samples. GLUT3 was knocked down in AGS and HGC27 cells and overexpressed in MKN45 cells to establish the corresponding experimental models. The CUT&Tag and ChIP-qPCR techniques were utilized to elucidate the GLUT3-histone H3 lysine 18 lactylation (H3K18la)-mitogen-activated protein kinase associated protein 1 (MAPKAP1) regulatory axis. A mouse peritoneal metastasis model was used to evaluate the ability of GLUT3 targeting to reverse ferroptosis resistance and paclitaxel chemoresistance.Results: GLUT3, glutathione peroxidase 4 (GPX4), and solute carrier family 7 member 11 (SLC7A11) expression was significantly upregulated in paclitaxel-resistant GCPM tissues. Elevated GLUT3 expression correlated with poor prognosis in GC patients. Functionally, GLUT3 knockdown sensitized GC cells to both Erastin and paclitaxel, whereas GLUT3 overexpression conferred therapeutic resistance. Mechanistically, GLUT3 upregulated hexokinase 3 (HK3) expression, increasing glucose-6-phosphate (G6P) and lactate production. Elevated lactate levels supported E1A binding protein p300 (p300)-mediated H3K18la enrichment at the MAPKAP1 promoter, thereby activating its transcription. Rescue assays indicated that depletion of MAPKAP1 restored ferroptosis sensitivity in GC cells. Conclusion: Targeting GLUT3-H3K18la-MAPKAP1 reverses paclitaxel resistance by inducing ferroptosis, providing a novel combination strategy for treating refractory GCPM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.